$Coya Therapeutics (COYA.US)$ NEWS Coya Therapeutics Announc...
NEWS
Coya Therapeutics Announces the Completion of a Controlled Phase 2 Study of Low Dose Interleukin-2 (LD IL-2) in Patients with Alzheimer’s Disease
Positive
Completion of Phase 2 study on schedule.
Study funded by the Gates Foundation and Alzheimer’s Association, indicating strong support.
Topline results expected by summer 2024.
Preliminary data showed significant improvements in cognitive function.
Significant enhancement in regulatory T cell (Treg) function and numbers.
No serious adverse events reported in preliminary studies.
No patient discontinued the study.
Negative
Study involved a small number of participants (38 patients).
Results from Phase 2 not yet available; uncertainty remains.
Previous studies were open-label with only 8 patients, limiting generalizability.
Completion of Phase 2 study on schedule.
Study funded by the Gates Foundation and Alzheimer’s Association, indicating strong support.
Topline results expected by summer 2024.
Preliminary data showed significant improvements in cognitive function.
Significant enhancement in regulatory T cell (Treg) function and numbers.
No serious adverse events reported in preliminary studies.
No patient discontinued the study.
Negative
Study involved a small number of participants (38 patients).
Results from Phase 2 not yet available; uncertainty remains.
Previous studies were open-label with only 8 patients, limiting generalizability.
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
Spread kindness and love. Life is short. Don’t let greed eat you.
1077Followers
68Following
7430Visitors
Follow